Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study

Peter M. Voorhees, Robert Z. Orlowski, Flora Mulkey, Peter Watson, Susan Geyer, Ben L. Sanford, Elizabeth Bennett, Asher A Chanan Khan, Clara D. Bloomfield, Richard A. Larson

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.

Original languageEnglish (US)
Pages (from-to)373-377
Number of pages5
JournalBritish Journal of Haematology
Volume171
Issue number3
DOIs
StatePublished - Nov 1 2015

Keywords

  • Anthracyclines
  • International staging system
  • Multiple myeloma
  • Proteasome inhibitors

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study'. Together they form a unique fingerprint.

  • Cite this